2. Academic Validation
  3. Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma

  • J Adv Pract Oncol. 2015 Jul-Aug;6(4):361-5. doi: 10.6004/jadpro.2015.6.4.6.
Lindsay Shelledy 1,  Danielle Roman 1
Affiliations

Affiliation

  • 1 West Penn Allegheny Oncology Network, Pittsburgh, Pennsylvania.
PMID: 26705496 DOI: 10.6004/jadpro.2015.6.4.6
Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z